Adenosquamous carcinoma of the pancreas harbors KRAS2, DPC4 and TP53 molecular alterations similar to pancreatic ductal adenocarcinoma

Jonathan R. Brody, Christina L. Costantino, Magdalena Potoczek, Joseph Cozzitorto, Peter McCue, Charles J. Yeo, Ralph H Hruban, Agnieszka K. Witkiewicz

Research output: Contribution to journalArticle

Abstract

Adenosquamous carcinoma of the pancreas is one of the most aggressive forms of pancreatic cancer. Molecular characterizations of this rare tumor subtype are sparse. Understanding the common molecular and pathologic features of pancreatic adenosquamous carcinomas could provide critical information for identifying therapeutic targets. Herein, we analyzed the pathologic and molecular features of our series of eight pancreatic adenosquamous carcinomas. We found KRAS2 gene mutations at codon 12 in all eight cases. All the cases showed loss of p16 protein. In three of these cases the loss was attributed to an exon 2 homozygous deletion in the p16/CDKN2a gene. The majority of the cases had loss of Dpc4 protein and strong nuclear p53 positivity, similar to the molecular signature found in pancreatic ductal adenocarcinoma. We found that E-cadherin was either lost or reduced in all cases and that epidermal growth factor receptor was overexpressed in all cases. The squamous component was positive for p63 staining and thus p63 labeling was helpful in identifying squamous differentiation in adenosquamous carcinomas with an acantholytic growth pattern. In summary, although pancreatic adenosquamous carcinoma and ductal adenocarcinoma have overlapping pathologic and molecular characteristics, there are distinct differences that may be helpful in diagnostic and therapeutic strategies.

Original languageEnglish (US)
Pages (from-to)651-659
Number of pages9
JournalModern Pathology
Volume22
Issue number5
DOIs
StatePublished - May 2009

Fingerprint

Adenosquamous Carcinoma
Pancreas
Adenocarcinoma
p16 Genes
Cadherins
Nuclear Proteins
Pancreatic Neoplasms
Epidermal Growth Factor Receptor
Codon
Exons
Staining and Labeling
Mutation
Therapeutics
Growth
Genes
Pancreatic Carcinoma
Neoplasms
Proteins

Keywords

  • Adenosquamous carcinoma
  • Dpc4
  • KRAS
  • P16
  • Pancreatic cancer

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Brody, J. R., Costantino, C. L., Potoczek, M., Cozzitorto, J., McCue, P., Yeo, C. J., ... Witkiewicz, A. K. (2009). Adenosquamous carcinoma of the pancreas harbors KRAS2, DPC4 and TP53 molecular alterations similar to pancreatic ductal adenocarcinoma. Modern Pathology, 22(5), 651-659. https://doi.org/10.1038/modpathol.2009.15

Adenosquamous carcinoma of the pancreas harbors KRAS2, DPC4 and TP53 molecular alterations similar to pancreatic ductal adenocarcinoma. / Brody, Jonathan R.; Costantino, Christina L.; Potoczek, Magdalena; Cozzitorto, Joseph; McCue, Peter; Yeo, Charles J.; Hruban, Ralph H; Witkiewicz, Agnieszka K.

In: Modern Pathology, Vol. 22, No. 5, 05.2009, p. 651-659.

Research output: Contribution to journalArticle

Brody, Jonathan R. ; Costantino, Christina L. ; Potoczek, Magdalena ; Cozzitorto, Joseph ; McCue, Peter ; Yeo, Charles J. ; Hruban, Ralph H ; Witkiewicz, Agnieszka K. / Adenosquamous carcinoma of the pancreas harbors KRAS2, DPC4 and TP53 molecular alterations similar to pancreatic ductal adenocarcinoma. In: Modern Pathology. 2009 ; Vol. 22, No. 5. pp. 651-659.
@article{2a6d866449a14784bcd9dcba402bc82c,
title = "Adenosquamous carcinoma of the pancreas harbors KRAS2, DPC4 and TP53 molecular alterations similar to pancreatic ductal adenocarcinoma",
abstract = "Adenosquamous carcinoma of the pancreas is one of the most aggressive forms of pancreatic cancer. Molecular characterizations of this rare tumor subtype are sparse. Understanding the common molecular and pathologic features of pancreatic adenosquamous carcinomas could provide critical information for identifying therapeutic targets. Herein, we analyzed the pathologic and molecular features of our series of eight pancreatic adenosquamous carcinomas. We found KRAS2 gene mutations at codon 12 in all eight cases. All the cases showed loss of p16 protein. In three of these cases the loss was attributed to an exon 2 homozygous deletion in the p16/CDKN2a gene. The majority of the cases had loss of Dpc4 protein and strong nuclear p53 positivity, similar to the molecular signature found in pancreatic ductal adenocarcinoma. We found that E-cadherin was either lost or reduced in all cases and that epidermal growth factor receptor was overexpressed in all cases. The squamous component was positive for p63 staining and thus p63 labeling was helpful in identifying squamous differentiation in adenosquamous carcinomas with an acantholytic growth pattern. In summary, although pancreatic adenosquamous carcinoma and ductal adenocarcinoma have overlapping pathologic and molecular characteristics, there are distinct differences that may be helpful in diagnostic and therapeutic strategies.",
keywords = "Adenosquamous carcinoma, Dpc4, KRAS, P16, Pancreatic cancer",
author = "Brody, {Jonathan R.} and Costantino, {Christina L.} and Magdalena Potoczek and Joseph Cozzitorto and Peter McCue and Yeo, {Charles J.} and Hruban, {Ralph H} and Witkiewicz, {Agnieszka K.}",
year = "2009",
month = "5",
doi = "10.1038/modpathol.2009.15",
language = "English (US)",
volume = "22",
pages = "651--659",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Adenosquamous carcinoma of the pancreas harbors KRAS2, DPC4 and TP53 molecular alterations similar to pancreatic ductal adenocarcinoma

AU - Brody, Jonathan R.

AU - Costantino, Christina L.

AU - Potoczek, Magdalena

AU - Cozzitorto, Joseph

AU - McCue, Peter

AU - Yeo, Charles J.

AU - Hruban, Ralph H

AU - Witkiewicz, Agnieszka K.

PY - 2009/5

Y1 - 2009/5

N2 - Adenosquamous carcinoma of the pancreas is one of the most aggressive forms of pancreatic cancer. Molecular characterizations of this rare tumor subtype are sparse. Understanding the common molecular and pathologic features of pancreatic adenosquamous carcinomas could provide critical information for identifying therapeutic targets. Herein, we analyzed the pathologic and molecular features of our series of eight pancreatic adenosquamous carcinomas. We found KRAS2 gene mutations at codon 12 in all eight cases. All the cases showed loss of p16 protein. In three of these cases the loss was attributed to an exon 2 homozygous deletion in the p16/CDKN2a gene. The majority of the cases had loss of Dpc4 protein and strong nuclear p53 positivity, similar to the molecular signature found in pancreatic ductal adenocarcinoma. We found that E-cadherin was either lost or reduced in all cases and that epidermal growth factor receptor was overexpressed in all cases. The squamous component was positive for p63 staining and thus p63 labeling was helpful in identifying squamous differentiation in adenosquamous carcinomas with an acantholytic growth pattern. In summary, although pancreatic adenosquamous carcinoma and ductal adenocarcinoma have overlapping pathologic and molecular characteristics, there are distinct differences that may be helpful in diagnostic and therapeutic strategies.

AB - Adenosquamous carcinoma of the pancreas is one of the most aggressive forms of pancreatic cancer. Molecular characterizations of this rare tumor subtype are sparse. Understanding the common molecular and pathologic features of pancreatic adenosquamous carcinomas could provide critical information for identifying therapeutic targets. Herein, we analyzed the pathologic and molecular features of our series of eight pancreatic adenosquamous carcinomas. We found KRAS2 gene mutations at codon 12 in all eight cases. All the cases showed loss of p16 protein. In three of these cases the loss was attributed to an exon 2 homozygous deletion in the p16/CDKN2a gene. The majority of the cases had loss of Dpc4 protein and strong nuclear p53 positivity, similar to the molecular signature found in pancreatic ductal adenocarcinoma. We found that E-cadherin was either lost or reduced in all cases and that epidermal growth factor receptor was overexpressed in all cases. The squamous component was positive for p63 staining and thus p63 labeling was helpful in identifying squamous differentiation in adenosquamous carcinomas with an acantholytic growth pattern. In summary, although pancreatic adenosquamous carcinoma and ductal adenocarcinoma have overlapping pathologic and molecular characteristics, there are distinct differences that may be helpful in diagnostic and therapeutic strategies.

KW - Adenosquamous carcinoma

KW - Dpc4

KW - KRAS

KW - P16

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=67349211022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349211022&partnerID=8YFLogxK

U2 - 10.1038/modpathol.2009.15

DO - 10.1038/modpathol.2009.15

M3 - Article

C2 - 19270646

AN - SCOPUS:67349211022

VL - 22

SP - 651

EP - 659

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 5

ER -